803 results on '"Castellano, D."'
Search Results
202. 796P - Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02
203. 790P - Proteomics profiling predicts poor prognosis in patients with muscle invasive urothelial carcinoma
204. 782PD - IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
205. 779PD - Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study
206. 753P - Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)
207. 726PD - Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study
208. 721PD - FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
209. 444P - Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study
210. Optimization of POLCA-controlled production systems with a simulation-driven genetic algorithm
211. Post-acute patient: what is the real meaning?
212. 773 Analysis of molecular profiling of renal cell carcinoma (RCC). Identification of a 4-microRNA signature as a prognostic value in patients with stage I-II
213. Recomendaciones sobre el manejo de controversias en cáncer de próstata avanzado resistente a la castración
214. Pazonet: A Phase II Trial of Pazopanib as a Sequencing Treatment in Progressive Metastatic Neuroendocrine Tumors (NETS) Patients (PTS), On Behalf of The Spanish Task Force for Nets (GETNE)
215. Cáncer de próstata resistente a castración: ¿hacia dónde vamos?
216. Sunitinib-induced hypertension in CYP3A4rs4646437 A-allele carriers with metastatic renal cell carcinoma
217. P3-05-06: Progression of Breast Cancer Molecular Subtypes through Different Clinical Stages.
218. P2-14-09: Comparison between Spanish and Peruvian Patients with Early Breast Cancer.
219. 7133 POSTER Treatment (tx) Patterns and Toxicity of Angiogenesis Inhibitors in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) in Spain
220. 7136 POSTER The Association Between Treatment (tx) Modifications Due to Adverse Events (AEs) and Overall Survival (OS) in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) Treated With Sunitinib and Sorafenib: Results From a Multi-country Study in Europe
221. Modelling Chaos? Sanitation Options; Support and Communication Tool
222. UP-02.062 Clinical, Biochemical and Radiologic Benefit of the Treatment with Sunitinib in Monotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer After Failure of Docetaxel
223. 6630 POSTER Evaluation of the Efficacy and the Safety of Lanreotide on Tumour Growth Stabilization in Patients With Progressive Neuroendocrine Tumours (NETs) Who Are Not Eligible to Be Treated With Either Surgery or Chemotherapy – TTD Group Study
224. 6564 POSTER Correlation of PFS With Early Response of Chromogranin A and 5-hydroxyindoleacetic Acid Levels in Pts With Advanced Neuroendocrine Tumours: Phase III RADIANT-2 Study Results
225. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).
226. PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment.
227. Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).
228. Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results.
229. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
230. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).
231. The MobiSan approach: informal settlements of Cape Town, South Africa
232. Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).
233. First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.
234. 295 RENAL NEOPLASMS: IS IT POSSIBLE TO DIAGNOSE THE GRADE WITH CORE BIOPSIES?
235. Sanitation services for the informal settlements of Cape Town, South Africa
236. MP-16.12: Survival Free of Disease and Chronic Toxicity for Localized Prostate Cancer Treated with Low Dose I 125 Permanent Prostate Brachytherapy
237. MP-18.12: Evaluation of Predictor Factors, of the Different aLHRH Available in Daily Clinical Practice, to Reach Castration Level (<20 Ng/Dl) in No Metastatic Prostate Cancer Patients
238. MP-14.16: Sunitinib Therapy for Patients with Advanced Renal Cell Carcinoma (ARCC): Analysis for Safety and Activity on Single Institution Experience: Favourable Overall Survival According MSKCC-Group Risk
239. 6653 Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen
240. 7038 Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC. A single institution experience
241. 7037 Clinical, biochemical (PSA) and radiographic benefit with sunitinib as a single agent in metastatic chemoresistant and hormone-refractory prostate cancer (HRPC) patients
242. 7152 Efficacy of Olmesartan Medoxomil for hypertension control in advanced RCC patients under treatment with single agent Sunitinib
243. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain
244. Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience
245. Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen
246. 48 LOW-DOSE KETOCONAZOLE IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS (HRPC): A SINGLE INSTITUTION EXPERIENCE
247. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts
248. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients (HRPC): A single institution experience
249. Sunitinib therapy for patients with advanced renal cell carcinoma (aRCC): Analysis for safety and activity on single institution experience—Prolonged overall survival
250. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.